Introduction
UC, cancer, PK/PD, human malignancy
GALLBLADDER CANCER, ONCOGENESIS, CANCER, SOLID TUMORS, SOLID TUMOR, SECONDARY, PANCREATIC CANCER
The fibroblast growth factor (FGF) signaling pathway is associated with oncogenesis of human malignancy [In recent years, a great deal of effort has been devoted to develop precise anti-cancer therapeutics by selectively targeting FGFRs: such as FGFR1-4 inhibitors of futibatinib (TAS-120) [There is still a large unmet medical need for precision therapy in cancer patients in China, however, none of the selective-FGFR inhibitors were approved in the country when this study was initiated. Although pemigatinib has been deeply investigated in Western population and demonstrated clinical benefit in CCA and RRMLN and antitumor activity signals in several types of solid tumor including pancreatic cancer, gallbladder cancer, UC, etc. with acceptable safety [This phase I, open-label study was conducted to investigate pemigatinib in Chinese patients with FGF/FGFR1-3 altered, advanced, metastatic or recurrent, solid tumors. The primary objective was to assess the pharmacokinetics/pharmacodynamics (PK/PD) of pemigatinib; secondary objectives included safety and efficacy.